RxDoctor Payments Data

Ben Jew, MD

Psychiatry · Portland, ORNPI 1275636680

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 34.0% of the total. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$781in general payments, 2019–2025

Across 37 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$265
  • Otsuka America Pharmaceutical, Inc.$211
  • E.r. Squibb & Sons, L.L.C.$166
  • Neurocrine Biosciences, Inc.$73
  • Johnson & Johnson$47
  • Alkermes, Inc.$19

What the payments were for

  • Food & beverage$75397%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$781 in reported general payments places this provider in the 90th percentile of 366 psychiatry providers in Oregon.

See all psychiatry providers in Oregon

Medicare billing

Part B allowed, 2024
$7,692
Medicare patients
20
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate15$117,668
Invega SustennaPaliperidone Palmitate17$47,749
Chlorpromazine Hcl13$15,039
Aripiprazole65$5,985
Clozapine119$4,966
Olanzapine154$3,393
Lurasidone Hcl65$3,203
Ziprasidone Hcl27$3,032
Paliperidone ErPaliperidone13$1,806
Benztropine Mesylate51$891
Trazodone Hcl52$749
Venlafaxine Hcl38$616
Quetiapine Fumarate ErQuetiapine Fumarate23$577
Divalproex Sodium ErDivalproex Sodium13$537
Carbamazepine14$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$47$165,41732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 366 psychiatry providers in Oregon.

Other psychiatry in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →